Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1996 1
1998 4
1999 1
2000 1
2002 1
2004 1
2012 1
2013 5
2014 2
2016 1
2019 1
2020 1
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. Online ahead of print. J Clin Oncol. 2024. PMID: 39265124
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration.
de Sequera P, Pérez-García R, Vega A, Martínez-Vaquera S, Acosta JG, Pérez Del Valle K, Fernández-Lucas M, García-Rubiales MA, García-Herrera AL, Coll E, Mérida E, Martínez-Miguel P, Castaño I, Gil-Casares B, Garro J, Maduell F; MOTheR collaborative network. de Sequera P, et al. Clin Kidney J. 2023 May 27;16(11):2254-2261. doi: 10.1093/ckj/sfad128. eCollection 2023 Nov. Clin Kidney J. 2023. PMID: 37915938 Free PMC article.
Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial.
Ruiz de Adana MS, Domínguez ME, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, García-Escobar E, Carreira M, Romero-Zerbo Y, Linares F, González-Mariscal I, Bermúdez-Silva FJ, Olveira G, Rojo-Martínez G. Ruiz de Adana MS, et al. Among authors: dominguez me. Diabetes Res Clin Pract. 2023 Feb;196:110238. doi: 10.1016/j.diabres.2023.110238. Epub 2023 Jan 5. Diabetes Res Clin Pract. 2023. PMID: 36610544 Clinical Trial.
Corrigendum to "Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial" [Diabetes Res. Clin. Pract. 196 (2023) 110238].
Ruiz-de-Adana MS, Domínguez ME, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, García-Escobar E, Carreira M, Romero-Zerbo Y, Linares F, González-Mariscal I, Bermúdez-Silva FJ, Olveira G, Rojo-Martínez G. Ruiz-de-Adana MS, et al. Among authors: dominguez me. Diabetes Res Clin Pract. 2024 Apr;210:111620. doi: 10.1016/j.diabres.2024.111620. Epub 2024 Mar 21. Diabetes Res Clin Pract. 2024. PMID: 38514300 No abstract available.
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, Sabatini CL, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, Salvadori MA, Acuña LA, Acuña JM, Langhi MJ, Amato S, Machiavelli MR. Leone BA, et al. Among authors: dominguez me. J Clin Oncol. 1996 Nov;14(11):2993-9. doi: 10.1200/JCO.1996.14.11.2993. J Clin Oncol. 1996. PMID: 8918497 Clinical Trial.
23 results